fda bpc 157 category 2 compounding 2023 BPC-157 Legal Status: Regulations and FDA is reviewing seven peptides

FDA is reviewing seven peptides this week, BPC 157, MOTS c, and Epitalon among them. Committee meets Thursday and Friday, and the likely outcome is tighter restrictions on compounding pharmacies. Read past the headline I am getting so many messages there is a lot to review and a lot unfolding quickly! I want to take my time with the information and have been studying on rotations. Hopefully will get yall an only This just in: The FDA is proposing to move 14 commonly used peptides from Category 2 to Category 1 on the compounding review list If finalized, this shift could significantly change A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring!

SKU: 40054673545 · From trustt.digital